Jagat Jyoti Mukherjee
Jagat Jyoti Mukherjee publishes mostly in Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery, on topics such as Diabetes Management and Research, Diabetes Treatment and Management and Adrenal and Paraganglionic Tumors.
- World rank
- #3,250,702 of 7,710,434 ranked researchers
- Rank in India
- #69,385 of 280,097
- Works
- 115
- Citations
- 2.7k
- Citations per work
- 23.8
What does Jagat Jyoti Mukherjee research?
Jagat Jyoti Mukherjee's work is mostly in Medicine (47%), Biochemistry, Genetics and Molecular Biology (12%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences5446.6%
- Medicine5446.6%
- Everything else4740.9%
- Life Sciences1412.5%
- 1Endocrinology, Diabetes and Metabolism25% of their works
- 2Molecular Biology12% of their works
- 3Surgery8% of their works
- 4Epidemiology6% of their works
- 5Neurology4% of their works
- 6Oncology4% of their works
Research topics
- Diabetes Management and Research
- Diabetes Treatment and Management
- Adrenal and Paraganglionic Tumors
- Pituitary Gland Disorders and Treatments
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Neuroendocrine Tumor Research Advances
- Neuroblastoma Research and Treatments
Which keywords describe Jagat Jyoti Mukherjee's research?
The keywords of their largest research topics: Glycemic Control, Insulin Therapy, Genetic Mutations, Cardiovascular Disease, Diabetes, Continuous Glucose Monitoring, Hypoglycemia and Cardiovascular Outcomes.
- Neuroendocrine Tumors
- Metabolic Syndrome
- ALK
- Critical Care
- Cushing's Syndrome
- Pheochromocytoma
- Cardiovascular Outcomes
- Continuous Glucose Monitoring
- Cardiovascular Disease
- Insulin Therapy
- Glycemic Control
- Genetic Mutations
- Diabetes
- Hypoglycemia
- Paraganglioma
- Type 2 Diabetes
- Pituitary Adenomas
- Hyperglycemia
- Insulin Resistance
- Neuroblastoma
- Pancreatic Neuroendocrine Tumors
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 21 words, with their numbers
- Glycemic Control333 topics
- Insulin Therapy333 topics
- Genetic Mutations253 topics
- Cardiovascular Disease202 topics
- Diabetes202 topics
- Continuous Glucose Monitoring131 topic
- Hypoglycemia131 topic
- Cardiovascular Outcomes111 topic
- Paraganglioma111 topic
- Pheochromocytoma111 topic
- Type 2 Diabetes111 topic
- Cushing's Syndrome101 topic
- Pituitary Adenomas101 topic
- Critical Care91 topic
- Hyperglycemia91 topic
- ALK71 topic
- Insulin Resistance71 topic
- Metabolic Syndrome71 topic
- Neuroblastoma71 topic
- Neuroendocrine Tumors71 topic
- Pancreatic Neuroendocrine Tumors71 topic
Where does Jagat Jyoti Mukherjee work?
Jagat Jyoti Mukherjee's main affiliation in the publication record is Apollo Gleneagles Hospitals, India.
How many publications and citations does Jagat Jyoti Mukherjee have?
OpenAlex counts 115 works and 2,738 citations for Jagat Jyoti Mukherjee, an h-index of 27, ranking #3,250,702 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Jagat Jyoti Mukherjee. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.